Microbiota, Mucus, and CFTR Modulators in Cystic Fibrosis Airway Infection Pathogenesis
Overview
Cystic fibrosis (CF) lung disease arises from defective CFTR function causing dehydrated mucus and impaired mucociliary clearance, fostering chronic polymicrobial airway infections dominated by pathogens such as Pseudomonas aeruginosa and Staphylococcus aureus. Highly effective CFTR modulators improve airway hydration and reduce pathogen density, yet chronic infections often persist, and the long-term effects of modulators on infection dynamics and clinical outcomes remain to be fully elucidated.
Background
CF is an autosomal recessive disorder caused by mutations in the CFTR gene leading to defective chloride and bicarbonate transport. This results in thickened mucus and impaired mucociliary clearance in the airways, creating an environment conducive to chronic bacterial infections. These infections, often polymicrobial and dominated by specific CF pathogens, drive cycles of inflammation and airway damage, ultimately causing progressive lung function decline. CFTR modulators such as ivacaftor and elexacaftor/tezacaftor/ivacaftor (ETI) target the underlying protein defect, improving ion transport and airway surface hydration.
Data Highlights
CF airway infections show age-related pathogen prevalence: early childhood infections are dominated by methicillin-susceptible Staphylococcus aureus and Haemophilus influenzae, while adolescence and adulthood see increased infections with methicillin-resistant S. aureus, Pseudomonas aeruginosa, Burkholderia, Stenotrophomonas, Achromobacter, and nontuberculous mycobacteria. Chronic P. aeruginosa infection correlates with increased pulmonary exacerbations, accelerated FEV1 decline, and higher mortality risk. Culture-independent sequencing reveals decreased bacterial diversity and dominance of pathogenic taxa as lung disease progresses.
Key Findings
CF airway infections are polymicrobial but often dominated by traditional CF pathogens that vary with patient age.
Chronic Pseudomonas aeruginosa infection is strongly associated with worsened lung function and increased mortality.
CFTR modulators improve airway hydration and mucociliary clearance, reducing pathogen acquisition and density.
Despite modulator therapy, many individuals with established infections remain chronically infected.
Culture-independent methods reveal loss of bacterial diversity and pathogen dominance correlating with disease progression.
Long-term impacts of CFTR modulators on airway infection dynamics and clinical outcomes are not yet fully understood.
Clinical Implications
CFTR modulators represent a significant advancement by targeting the underlying ion transport defect, improving mucus clearance and reducing infection burden. However, clinicians should recognize that chronic infections often persist despite modulator therapy, necessitating continued monitoring and management of airway pathogens. Understanding changes in airway microbiota and infection patterns in the modulator era will inform optimized infection control strategies and personalized treatment approaches.
Conclusion
The advent of CFTR modulators has transformed CF care by improving airway environment and reducing infection severity, yet chronic airway infections remain a challenge. Ongoing research into microbiota dynamics and long-term infection outcomes is essential to refine therapeutic strategies in the CFTR modulator era.
References
Author/Source/Year -- The Role of Microbiota, Mucus, and Therapeutic Modulators in the Pathogenesis of Infections in Cystic Fibrosis During the Era of CFTR Modulator Treatments
